You wake up one morning, and the vision in your central field — the sharp vision you use to read, recognize faces, and drive — is no longer crisp. It feels dimmed, like looking through a rain-streaked window. You have clear vision in the corners, but the middle, the part you depend on, has lost focus. You see an eye specialist, undergo OCT imaging, and are told: you have central serous chorioretinopathy. Fluid has leaked from the choroid — the blood-rich layer beneath the retina — and is pooling beneath the photoreceptors at the macula. The reassuring part: most cases resolve within three to six months without any intervention whatsoever. What you need to understand is how that happens, why it sometimes does not, and what your role is in the management process.

What Is Central Serous Chorioretinopathy?

Central serous chorioretinopathy, abbreviated CSR or CSCR, is a condition in which the neurosensory retina — the light-sensing tissue at the back of the eye — becomes separated from its underlying pigment epithelium by a pocket of fluid. This fluid originates from the choroid, a vascular plexus that normally supplies the outer retina with oxygen and nutrients. In CSR, the choroid becomes abnormally "leaky" — likely due to local vascular dysfunction and the action of inflammatory and vasoactive substances — and fluid seeps through the retinal pigment epithelium into the subretinal space.

The macula is the most sensitive region of the retina, responsible for the detailed, colour vision that permits reading, recognizing faces, and driving. When fluid accumulates beneath it, central vision blurs, colours become desaturated, and objects may appear smaller than they truly are (a phenomenon called micropsia). Because the condition is confined to the macula, peripheral vision remains intact — a distinguishing feature from more widespread retinal disease.

"In central serous chorioretinopathy, the macula is temporarily detached by a thin layer of fluid originating from the blood vessels below. Most often, the eye reabsorbs this fluid naturally over weeks to months. The key is distinguishing acute self-limiting disease from chronic recurrent patterns that warrant earlier intervention."

— Dr. Wong Chee Wai

Who Gets It and Why

Central serous chorioretinopathy predominantly affects adults in their 30s to 50s, with a striking male predominance — approximately 4 to 5 men for every woman affected. It is not a rare disease: population-based studies estimate an annual incidence of approximately 5-10 per 100,000 population, with higher prevalence in developed nations and in certain ethnic groups (particularly Caucasian and Hispanic populations).

Risk Factors and Triggers

CSR is multifactorial. No single cause accounts for all cases, but several well-established risk factors substantially elevate risk:

The Steroid Connection

If you are on systemic corticosteroids and develop CSR, the absolute priority is discussion with your prescribing physician regarding dose reduction or alternative therapies. CSR often resolves within weeks to months of steroid discontinuation. In some cases, the steroid cannot be stopped (e.g., critical autoimmune disease), but even dose reduction helps.

Symptoms and Presentation

Central serous chorioretinopathy presents acutely. Patients describe the onset as sudden or subacute — developing over hours to days, not gradually over weeks. Characteristic symptoms include:

Importantly, peripheral vision is unaffected. Patients retain good side vision and can navigate without difficulty — it is the central field that is compromised. This constellation of central visual loss with preserved peripheral vision is diagnostically useful and can help exclude other retinal conditions that produce more widespread visual field defects.

How Is CSR Diagnosed?

Diagnosis relies on imaging, not visual acuity testing alone. Several imaging modalities are employed depending on the clinical context:

Optical Coherence Tomography (OCT)

OCT is the gold standard for diagnosing CSR and monitoring the condition. The cross-sectional image shows the subretinal fluid pocket clearly — the neurosensory retina is visibly separated from the retinal pigment epithelium and choriocapillaris by a layer of low-reflectivity (dark) fluid. OCT also reveals the thickness of the retina and permits assessment of photoreceptor integrity (the ellipsoid zone). In chronic CSR, repeated episodes cause progressive damage to the retinal pigment epithelium and photoreceptor outer segments, visible as disrupted ellipsoid zones and areas of RPE atrophy. OCT imaging is repeated serially to document resolution and identify any recurrences.

Fluorescein Angiography (FA)

Fluorescein angiography reveals the source of the fluid leak — the point where fluid is seeping through the retinal pigment epithelium from the choroid below. A characteristic "inkblot" pattern of hyperfluorescence expands from the leak site during the mid-phase and late-phase images. FA also shows whether the leak is focal (single point) or multifocal (multiple leak sites), which may influence treatment decisions. FA is particularly useful for defining leak location prior to laser or photodynamic therapy.

Indocyanine Green Angiography (ICG-A)

ICG-A penetrates the retinal pigment epithelium and visualizes the choroidal circulation. In CSR, ICG-A often reveals choroidal hyperpermeability — abnormal dilation of choroidal vessels and leakage from the choroid itself. Multifocal areas of choroidal vascular dilation (a pattern called "pinpoint leaks") can be seen. ICG-A is particularly useful in chronic CSR and in guiding photodynamic therapy (PDT), which is specifically designed to close choroidal sources of leakage.

Acute Versus Chronic CSR

CSR has two distinct temporal patterns, with markedly different prognoses and management implications:

Acute Central Serous Chorioretinopathy

Acute CSR is the first or early episode in a patient with no prior history of the condition. Most acute CSR episodes — estimated at 85-90% — resolve spontaneously within 3 to 6 months as the subretinal fluid is gradually reabsorbed. Visual acuity typically recovers to near pre-morbid levels, though some patients may retain mild residual symptoms. The prognosis is generally excellent unless there is associated retinal pigment epithelium damage, which can be seen on OCT as disrupted ellipsoid zones.

The natural history suggests that observation — careful monitoring with serial OCT imaging without active treatment — is the appropriate first-line approach in most acute cases. Treatment is deferred unless resolution is delayed beyond 3-6 months or visual symptoms are particularly severe and intolerable to the patient.

Chronic Central Serous Chorioretinopathy

Chronic CSR encompasses two scenarios: (1) persistent fluid in the same eye beyond 3-6 months from initial onset (termed "diffuse" or "recurrent" CSR depending on the extent of RPE changes), and (2) recurrent episodes in the same eye, with fluid resolving between episodes but recurring weeks to months later. Recurrence rates in CSR are substantial — approximately 30-50% of patients experience at least one recurrence within 5 years. Chronic CSR has a less favourable prognosis because repeated episodes cause cumulative photoreceptor and retinal pigment epithelium damage, leading to slower or incomplete recovery of vision. In some chronic cases, permanent visual loss occurs due to irreversible photoreceptor atrophy or RPE scarring.

Chronic CSR warrants more aggressive management. Treatment options include photodynamic therapy (PDT), micropulse laser photocoagulation, and anti-VEGF intravitreal injections, depending on the imaging characteristics and clinical scenario.

Will It Go Away on Its Own?

The short answer: yes, in most acute cases. The longer answer: it depends on which category of CSR you have, how long you are willing to wait, and how much visual impairment you can tolerate.

In acute CSR, spontaneous resolution occurs in the majority of patients within 3-6 months. The fluid is gradually reabsorbed by the eye's natural mechanisms — a process that remains incompletely understood, but involves restoration of the barrier function of the retinal pigment epithelium and improved clearance of fluid back into the choroid. For patients whose vision is mildly affected and who can be monitored reliably with periodic OCT imaging, observation is a reasonable and cost-effective approach.

However, if resolution is delayed beyond 6 months ("subacute" CSR), if visual symptoms are severely impairing daily function (e.g., inability to work due to blurred vision), or if recurrences are frequent and threatening long-term vision, intervention becomes increasingly justified. The goal of treatment in these cases is to accelerate closure of the choroidal leak and speed reabsorption of fluid, thereby protecting the macula from prolonged exposure to detached photoreceptors.

85–90%

of acute CSR cases resolve spontaneously within 3–6 months
Most achieve visual recovery to near baseline or better

When Treatment Is Needed

Several scenarios warrant active intervention rather than observation alone:

Photodynamic Therapy (PDT)

PDT is the most evidence-based and widely used treatment for CSR. The procedure involves intravenous injection of a photosensitizing dye (verteporfin) that accumulates in the abnormal choroidal vessels, followed by targeted laser activation (wavelength 689 nm) of the dye. The activated dye generates reactive oxygen species that selectively damage the endothelial cells of the abnormal choroidal vasculature, leading to closure of the leak. PDT is performed as an outpatient procedure, takes approximately 20 minutes, and causes minimal discomfort. Studies show that PDT can accelerate resolution of subretinal fluid and may reduce recurrence risk. It is particularly valuable in chronic or recurrent CSR.

Micropulse Laser Photocoagulation

Micropulse laser delivers short bursts of therapeutic laser energy rather than continuous laser. It can be applied directly to the leak site identified on fluorescein angiography. Micropulse laser has the advantage of lower risk of retinal scarring compared with continuous-wave laser photocoagulation, making it preferable in treating central or near-foveal leaks. Some studies show efficacy comparable to PDT in selected cases, and the procedure is less costly.

Anti-VEGF Intravitreal Injections

Intravitreal anti-VEGF agents (such as ranibizumab, bevacizumab, or aflibercept) have shown benefit in some CSR cases, particularly those with prominent choroidal vascular dilation on ICG-A. The mechanism is thought to involve suppression of vascular endothelial growth factor, which contributes to abnormal choroidal vascularity. Anti-VEGF is increasingly used in conjunction with PDT or as a standalone therapy in selected patients. Multiple injections are often required over several months.

Lifestyle Modifications and Supportive Care

Stress reduction and relaxation: Given the documented association between psychological stress and CSR exacerbation, stress management is recommended. This may include counselling, mindfulness practices, regular exercise, and adequate sleep.

Discontinuation of corticosteroids: If CSR occurs in a patient on systemic steroids, urgent discussion with the prescribing physician regarding dose reduction or discontinuation is warranted. Many cases resolve within weeks of steroid cessation.

Caffeine and salt intake: Some practitioners recommend limiting caffeine and sodium, though evidence is limited. The rationale is that both agents may contribute to choroidal vasodilation or fluid accumulation. Anecdotal patient reports suggest benefit, but randomized data are lacking.

Eye drops and anti-inflammatory agents: Topical nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroid eye drops are sometimes used to reduce inflammation and support healing, though the evidence for benefit is not robust.

Frequently Asked Questions

Will my CSR come back?

Recurrence is unfortunately common. Approximately 30-50% of patients experience at least one recurrence within 1-5 years of the initial episode. Some patients have multiple recurrences over their lifetime — a pattern termed "chronic recurrent CSR." Factors that may increase recurrence risk include ongoing psychological stress, continued corticosteroid use, chronic underlying choroidal vascular abnormalities, and unmodified lifestyle factors. Each recurrence typically responds to the same management as the initial episode, though the prognosis for complete recovery may be slightly less favorable if prior episodes have caused photoreceptor damage.

Is CSR caused by stress?

Stress is a recognized and important trigger, but it is not the sole cause. CSR is multifactorial. Psychological stress, particularly acute life stressors, can precipitate attacks in susceptible individuals — likely through neuroendocrine and inflammatory pathways that increase choroidal vascular permeability. However, not all CSR is stress-related. Corticosteroid use, hormonal factors, and underlying choroidal vascular abnormalities contribute independently. Managing stress and implementing relaxation strategies may reduce recurrence risk but will not prevent CSR in someone with inherent choroidal dysfunction or active steroid use.

Does CSR cause permanent vision loss?

In acute CSR, permanent vision loss is uncommon. As the fluid reabsorbs over weeks to months, vision typically recovers to baseline or near-baseline levels. However, chronic CSR — characterized by persistent fluid or repeated recurrences — can lead to permanent visual impairment. Prolonged detachment of the photoreceptors and repeated episodes cause cumulative damage to the retinal pigment epithelium and photoreceptor layer. Patients with chronic CSR may experience slower recovery, residual visual symptoms (mild metamorphopsia, colour desaturation), or permanent loss of several lines of visual acuity. Early intervention in chronic cases may mitigate this risk.

Can I exercise during CSR?

Physical activity does not cause CSR or worsen the underlying condition. However, during the acute phase, intense exertion or Valsalva manoeuvres (straining, heavy lifting, bearing down) may transiently worsen visual symptoms. Moderate exercise — walking, light cycling, swimming — can usually be continued without difficulty. As the fluid reabsorbs and vision improves, return to more vigorous exercise is appropriate. Many athletes have successfully returned to full training during ongoing CSR. The key is to avoid straining in the acute phase and to monitor for any visual change that might indicate progression or recurrence.

What is the connection between steroids and CSR?

Systemic corticosteroids are the strongest identifiable risk factor for CSR. The risk increases with dose — particularly at doses exceeding 5-10 mg daily of prednisone equivalent — and with duration of use. Steroid-induced CSR can develop weeks to months after starting treatment. The mechanism is thought to involve corticosteroid effects on the retinal pigment epithelium and choroidal vasculature. If you develop CSR while on steroids, inform your prescribing physician immediately. In many cases, CSR resolves within weeks of dose reduction or discontinuation. If continued steroid therapy is absolutely necessary (e.g., for critical autoimmune disease), the lowest effective dose should be maintained, and ophthalmologic monitoring should be intensified.

When should I seek urgent care for CSR?

Seek urgent evaluation from an eye specialist if you develop sudden blurred or dimmed central vision, particularly if accompanied by metamorphopsia or a central scotoma. While CSR itself is not immediately sight-threatening, rapid onset of symptoms warrants prompt assessment to confirm diagnosis and establish a baseline against which to monitor progression. Also seek urgent evaluation if symptoms develop while you are on corticosteroids, as medication adjustment may be necessary. If you have had CSR previously and experience similar visual symptoms, contact your specialist promptly — recurrence is common, and early documentation with imaging can guide treatment decisions.

Research by Dr. Wong

Selected peer-reviewed publications by Dr. Wong on macular disease, choroidal pathophysiology, and treatment of central serous chorioretinopathy.